Long-term survival of patients with pulmonary arterial hypertension recovering to World Health Organization functional class I or II: a historical comparison between intravenous epoprostenol and oral agents

BACKGROUND: Intravenous epoprostenol is the only drug proved in a randomized study to reduce mortality in patients with idiopathic pulmonary arterial hypertension (PAH). However, administration of this drug has procedural difficulties and a risk of sepsis. Oral drugs provide simple treatment, but th...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamamoto, Koji, Takeda, Yutaka, Takeda, Yasuko, Naniwa, Taio, Narita, Hitomi, Ohte, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082170/
https://www.ncbi.nlm.nih.gov/pubmed/24920465
http://dx.doi.org/10.1186/1756-0500-7-359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082170/
https://www.ncbi.nlm.nih.gov/pubmed/24920465
http://dx.doi.org/10.1186/1756-0500-7-359

Ejemplares similares